MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

At 21-42 days post-vaccination, the geometric mean haemagglutination inhibition titres were 32% higher for H1N1, 55% for H3N2, and 39% for B strains among recipients of the high-dose vaccine than ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu ...

Amid promising signs, officials urged caution, noting that the outbreaks vary by clade, response measures, and social ...

Presented by Vaccinate Your Family{beacon} Health Care Health Care   The Big Story Senate set to vote on amendment rolling ...

Over a dozen U.S. citizens have been swept up in the Trump administration’s crackdown on immigration, according to interviews, court records and news reports.

Army Commander Northern Command, Lieutenant General Pratik Sharma, on Saturday Visited the Strategic Strikers and Reviewed the Operational Preparedness. "Lt Gen Pratik Sharma, ...

Lauren Weber joined The Washington Post in 2023 as an accountability reporter focused on the forces promoting scientific and medical disinformation. She previously investigated the decimated ...

Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza.

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza ...